Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Ameriprise Financial Inc. bought a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 35,059 shares of the company's stock, valued at approximately $789,000. Ameriprise Financial Inc. owned 0.07% of Enliven Therapeutics as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ELVN. Boxer Capital Management LLC acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at about $15,106,000. FMR LLC boosted its position in Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after acquiring an additional 199,692 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock worth $21,877,000 after acquiring an additional 135,969 shares during the last quarter. Federated Hermes Inc. acquired a new position in Enliven Therapeutics during the fourth quarter worth about $2,645,000. Finally, Artia Global Partners LP acquired a new position in Enliven Therapeutics during the fourth quarter worth about $2,315,000. Institutional investors and hedge funds own 95.08% of the company's stock.

Enliven Therapeutics Stock Up 2.0%

NASDAQ:ELVN traded up $0.43 on Wednesday, hitting $22.29. The stock had a trading volume of 591,000 shares, compared to its average volume of 265,651. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -11.73 and a beta of 1.07. The company has a fifty day moving average price of $17.99 and a two-hundred day moving average price of $20.87. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the transaction, the chief executive officer now directly owns 990,392 shares in the company, valued at $20,629,865.36. The trade was a 1.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Anish Patel sold 6,667 shares of the business's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $21.44, for a total transaction of $142,940.48. Following the completion of the transaction, the chief operating officer now owns 323,310 shares in the company, valued at $6,931,766.40. The trade was a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 86,111 shares of company stock worth $1,643,398 in the last ninety days. 29.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Jones Trading lowered their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. HC Wainwright boosted their price target on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Enliven Therapeutics has an average rating of "Buy" and an average target price of $37.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.